Management of treatment refractory attention-deficit/hyperactivity disorder in children and adolescents.

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Psychostimulants are the first-line treatment for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. A minimum of two psychostimulant trials should be instituted before a child's symptoms of ADHD are considered treatment refractory. Clinical issues of diagnostic accuracy, comorbid disorders, psychosocial factors, medication compliance, symptoms across settings, and behavioral treatment should be addressed before initiating alternative medication trials. With the exception of tricyclic antidepressants, there is a paucity of controlled studies with adequate sample size to support the efficacy and safety of nonstimulant medications for the treatment of childhood ADHD. In this article, data on medications for treatment refractory ADHD in children and adolescents are presented and treatment strategies are discussed.

Original languageEnglish (US)
Pages (from-to)130-142
Number of pages13
JournalPsychopharmacology Bulletin
Volume36
Issue number1
StatePublished - Dec 2002

Fingerprint

Attention Deficit Disorder with Hyperactivity
Therapeutics
Medication Adherence
Tricyclic Antidepressive Agents
Sample Size
Psychology
Safety

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Management of treatment refractory attention-deficit/hyperactivity disorder in children and adolescents. / Wagner, Karen.

In: Psychopharmacology Bulletin, Vol. 36, No. 1, 12.2002, p. 130-142.

Research output: Contribution to journalArticle

@article{ee2c5d501a104cf58db7bc4c3290007c,
title = "Management of treatment refractory attention-deficit/hyperactivity disorder in children and adolescents.",
abstract = "Psychostimulants are the first-line treatment for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. A minimum of two psychostimulant trials should be instituted before a child's symptoms of ADHD are considered treatment refractory. Clinical issues of diagnostic accuracy, comorbid disorders, psychosocial factors, medication compliance, symptoms across settings, and behavioral treatment should be addressed before initiating alternative medication trials. With the exception of tricyclic antidepressants, there is a paucity of controlled studies with adequate sample size to support the efficacy and safety of nonstimulant medications for the treatment of childhood ADHD. In this article, data on medications for treatment refractory ADHD in children and adolescents are presented and treatment strategies are discussed.",
author = "Karen Wagner",
year = "2002",
month = "12",
language = "English (US)",
volume = "36",
pages = "130--142",
journal = "Psychopharmacology Bulletin",
issn = "0048-5764",
publisher = "MedWorks Media LLC",
number = "1",

}

TY - JOUR

T1 - Management of treatment refractory attention-deficit/hyperactivity disorder in children and adolescents.

AU - Wagner, Karen

PY - 2002/12

Y1 - 2002/12

N2 - Psychostimulants are the first-line treatment for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. A minimum of two psychostimulant trials should be instituted before a child's symptoms of ADHD are considered treatment refractory. Clinical issues of diagnostic accuracy, comorbid disorders, psychosocial factors, medication compliance, symptoms across settings, and behavioral treatment should be addressed before initiating alternative medication trials. With the exception of tricyclic antidepressants, there is a paucity of controlled studies with adequate sample size to support the efficacy and safety of nonstimulant medications for the treatment of childhood ADHD. In this article, data on medications for treatment refractory ADHD in children and adolescents are presented and treatment strategies are discussed.

AB - Psychostimulants are the first-line treatment for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. A minimum of two psychostimulant trials should be instituted before a child's symptoms of ADHD are considered treatment refractory. Clinical issues of diagnostic accuracy, comorbid disorders, psychosocial factors, medication compliance, symptoms across settings, and behavioral treatment should be addressed before initiating alternative medication trials. With the exception of tricyclic antidepressants, there is a paucity of controlled studies with adequate sample size to support the efficacy and safety of nonstimulant medications for the treatment of childhood ADHD. In this article, data on medications for treatment refractory ADHD in children and adolescents are presented and treatment strategies are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0036886347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036886347&partnerID=8YFLogxK

M3 - Article

C2 - 12397852

AN - SCOPUS:0036886347

VL - 36

SP - 130

EP - 142

JO - Psychopharmacology Bulletin

JF - Psychopharmacology Bulletin

SN - 0048-5764

IS - 1

ER -